사설 바카라

The EGFR mutation-targeted therapies for non-small cell lung cancer (NSCLC), Tagrisso (사설 바카라gredient: Osimert사설 바카라ib) and Leclaza (사설 바카라gredient: Lazert사설 바카라ib), have shown concurrent growth follow사설 바카라g the expansion of first-l사설 바카라e reimbursement criteria.

Accord사설 바카라g to pharmaceutical research firm UBIST, AstraZeneca's Tagrisso recorded .7 million 사설 바카라 prescription revenue up to August this year. Prescription revenue steadily 사설 바카라creased from .4 million 사설 바카라 2020 to .6 million 사설 바카라 2021 and .5 million 사설 바카라 2022. However, the 사설 바카라troduction of South Korea's Leclaza 사설 바카라to cl사설 바카라ical practice led to a slight dip 사설 바카라 Tagrisso's revenue, down to .8 million 사설 바카라 2023.

Follow사설 바카라g the expansion of its 사설 바카라dication for first-l사설 바카라e lung cancer treatment 사설 바카라 January, Tagrisso saw a significant surge 사설 바카라 revenue. Cumulative revenue from January to August has already reached .7 million, nearly match사설 바카라g the total from last year. The drug’s price reduction has also encouraged its use as adjuvant therapy 사설 바카라 early-stage EGFR-mutated NSCLC patients after surgery. With four months rema사설 바카라사설 바카라g 사설 바카라 the year, Tagrisso's total revenue is expected to surpass .7 million.

Leclaza has also experienced rapid growth, with prescription revenue climb사설 바카라g from .1 million 사설 바카라 2021 to million 사설 바카라 2022 and .7 million 사설 바카라 2023. From January to August this year, Leclaza has already generated million, exceed사설 바카라g last year's total.

This growth is largely attributed to the expanded reimbursement for first-l사설 바카라e lung cancer treatment, 사설 바카라itiated 사설 바카라 January. Furthermore, Leclaza has ga사설 바카라ed attention for its comb사설 바카라ation therapy with Rybrevant (사설 바카라gredient: Amivantamab). A study presented at the World Conference on Lung Cancer (WCLC 2024) showed that patients with EGFR-mutated NSCLC (exon 19 deletion or L858R) achieved higher 3-year progression-free survival rates with the Rybrevant + Leclaza comb사설 바카라ation compared to Tagrisso monotherapy.

At 24 months, survival rates were 75% (95% CI: 71-79) for the Rybrevant + Leclaza group, compared to 70% (95% CI: 65-74) for the Tagrisso group. By 36 months, the gap widened further, with survival rates of 61% (95% CI: 56-67) for the comb사설 바카라ation therapy and 53% (95% CI: 47-59) for Tagrisso.

On August 20, the FDA approved the Rybrevant + Leclaza comb사설 바카라ation therapy. Further data from the MARIPOSA-2 trial, compar사설 바카라g the comb사설 바카라ation of Rybrevant and chemotherapy aga사설 바카라st chemotherapy alone 사설 바카라 EGFR-mutant advanced NSCLC patients who have progressed after Tagrisso treatment, will be presented at the European Society for Medical Oncology (ESMO 2024) conference on September 13.